The only prescription vitamin K tablet available in the US

MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

MEPHYTON tablets are indicated in:

  • anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives;
  • hypoprothrombinemia secondary to antibacterial therapy;
  • hypoprothrombinemia secondary to administration of salicylates;
  • hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed1

MEPHYTON acts just like naturally occurring vitamin K, requires bile salts for absorption from the gastrointestinal tract, and generally exerts its effect within 6 to 10 hours.1

Adults Initial Dosage
Anticoagulant-induced prothrombin deficiency (caused by coumarin or indianedione derivatives) 2.5 mg-10 mg or up to 25 mg (rarely 50 mg)
Hypoprothrombinemia due to other causes (Antibiotics; Salicylates or other drugs; Factors limiting absorption or synthesis) 2.5 mg-25 mg or more (rarely up to 50 mg)

Indications
MEPHYTON® (PHYTONADIONE) is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX, and X when caused by vitamin K deficiency or interference with vitamin K activity.

MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed.

Important Safety Information
MEPHYTON (PHYTONADIONE) is contraindicated in patients with hypersensitivity to any component of this medication. An immediate coagulation effect should not be expected after administration. MEPHYTON will not counteract the anticoagulant action of heparin. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly. Failure to respond to vitamin K may indicate a congenital coagulation defect or that the condition being treated is unresponsive to vitamin K. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

PLEASE SEE FULL PRESCRIBING INFORMATION.

Reference: 1. MEPHTYON [package insert]. Lawrenceville, NJ: Aton Pharma; 2009.

prescribing information save on mephyton patient care program